Pfizer and BioNTech will submit a request on November 20 to the U.S. Food and Drug Administration for emergency use authorization (EUA) of their messenger RNA vaccine candidate, BNT162b2, against infection with the SARS-CoV-2 virus.
Similar safety and immunogenicity profiles were observed in adults and older adults who received the Oxford/AstraZeneca SARS-CoV-2 vaccine candidate, ChAdOx1 nCoV-19, according to data from the phase II clinical trial. The findings were published in the Lancet on November 18. Discuss
Particles for Humanity has secured a $5 million grant from the Bill & Melinda Gates Foundation, which it plans to use to develop a single injection vaccine delivery technology.
Pfizer and BioNTech have passed another milestone in their effort to deliver a vaccine for the SARS-CoV-2 virus. The companies on November 18 reported that their BNT162b2 vaccine candidate has met safety milestones and that they plan to apply for an emergency use authorization (EUA) from the U.S. Food and Drug Administration for the product in the coming days. Discuss
Researchers have shed light on the "known unknowns" of preexisting and acquired T-cell responses in relation to SARS-CoV-2 infection. In a perspective piece, published in Science Immunology on November 18, scientists from Karolinska Institutet in Sweden discuss the role and durability of T-cell responses in COVID-19. Discuss
The COVID-19 High Performance Computing Consortium said that it has entered a new phase of operation focused on helping researchers identify potential near-term therapies for COVID-19 patients.
Eli Lilly and Samsung Biologics have signed a long-term partnership for manufacturing of Lilly's COVID-19 antibody therapies.
Moderna said that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use has initiated a rolling review of the firm's messenger RNA (mRNA)-1273 COVID-19 vaccine candidate. The company has also inked an agreement to supply the vaccine to the U.K. government.
The U.S. Food and Drug Administration (FDA) Commissioner Dr. Stephen Hahn reaffirmed the agency's commitment to transparency regarding the emergency use authorization (EUA) process, including decisions to issue, revise, or revoke them.
The European Commission approved a fifth contract with CureVac for the initial purchase of 225 million doses on behalf of all European Union (EU) member states, plus an option to request up to an additional 180 million doses.
Insights
Exclusive content for Science Advisory Board members on trends and outcomes that are influencing the future of scientific research.
Communities
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Rewards
Earn points for contributing to research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Connect
